After selling a medical device company to the global market leader, one technology didn't go with the deal. A wearable clinical activity monitor with extensive validation data, used to track patient outcomes in movement disorders and rehabilitation. Most firms would have written it off as a residual asset. Acumen saw a company waiting to be built.

Digital health wearables were flooding the consumer market, but almost none had cleared the bar for clinical use. The gap between a fitness tracker and a reimbursable medical device is enormous: clinical validation, regulatory positioning, and a reimbursement pathway that most digital health companies never figure out. Without federal reimbursement, the technology would remain a research tool used in academic studies. It would never reach the patients and clinicians who needed it most.

Acumen spun the technology into a standalone company and made a strategic decision that shaped everything that followed. Rather than positioning it as a consumer wearable, we positioned it as a clinical device. That reframing opened a reimbursement pathway through the Veterans Administration, making it one of the first digital health wearable technologies to secure federal reimbursement. To minimize the need for equity investment, Acumen then structured a distribution arrangement that included financing to support production of the next-generation device.

The spinoff secured VA reimbursement approval and continues as an independent operating business, putting clinical-grade activity monitoring into the hands of providers treating veterans and patients with mobility challenges.

Sometimes the most valuable thing in a deal is what doesn't sell.